NASDAQ$SKIN
SkinHealth Systems Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Reported record financial results, exceeding expectations and raised net sales guidance for 2022.
BeautyHealth announced record second-quarter results with net sales growth of 55.7% year-over-year, reaching $103.5 million. The company raised its full-year net sales guidance and reaffirmed its adjusted EBITDA outlook, driven by strong demand for HydraFacial delivery systems and healthy consumer interest.
- Net sales increased by 55.7% year-over-year to $103.5 million.
- Net income reached $7.9 million, a significant improvement compared to a net loss of $139.4 million in the same quarter last year.
- Adjusted EBITDA grew by 10.9% to $12.6 million.
- Americas net sales increased by 76.6% year-over-year, driven by strong demand for Syndeo.
Headline financials
Revenue & EPS history
Beauty Health · Revenue · Quarterly
$104M
Revenue by segment
Beauty Health · $104M total across 2 segments · Q2 2022
- Delivery Systems$64.8M+85.7%62.5%
- Consumables$38.8M+22.8%37.5%
Forward guidance
BeautyHealth increased its fiscal 2022 net sales guidance to a range of $340.0 million to $350.0 million and reaffirmed its 2022 adjusted EBITDA outlook of approximately $50.0 million.
Tailwinds
- Increased fiscal 2022 net sales guidance reflects management's confidence in the business.
- Reaffirmation of 2022 adjusted EBITDA outlook indicates continued profitability expectations.
- Guidance assumes no material deterioration in general market conditions.
- Company continues to expect up to $20.0 million of capital expenditures to be incurred during 2022.
- The increase reflects management's confidence in the business as the Company executes against its growth plan.
Headwinds
- Achievement of anticipated results is subject to risks and uncertainties disclosed in SEC filings.
- Outlook does not account for unanticipated developments, changes in operating environment, acquisitions, dispositions, or financings during 2022.
- Company remains cautious of potential risks from COVID-19 strains and uneven global vaccine adoption.
- Inflationary headwinds related to higher raw material, shipping, and labor costs are a concern.
- Outlook assumes a largely reopened global market, which could be negatively impacted by closures or restrictive measures.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
+0.6%
Avg return
Earnings day
-0.5%
Avg return
5 days after
-1.9%
Avg return
30 days after
52%
12 / 23 earnings
Positive
+52.1%
Q1 2025
Best reaction
-61.4%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.5% | -29.9% | -34.9% | |
| Q4 2025 | +19.8% | +11.3% | -15.3% | |
| Q3 2025 | +8.7% | +3.1% | +13.2% | |
| Q1 2025 | +52.1% | +19.4% | +29.0% | |
| Q4 2024 | -5.6% | -9.9% | -26.1% | |
| Q3 2024 | +5.1% | -13.1% | -14.2% | |
| Q2 2024 | -10.4% | +0.8% | +12.8% | |
| Q1 2024 | -20.1% | -18.4% | -39.9% | |
| Q4 2023 | +16.8% | -0.8% | +4.4% | |
| Q3 2023 | -61.4% | -37.2% | -14.7% | |
| Q2 2023 | -6.0% | -12.9% | -24.2% | |
| Q1 2023 | -2.8% | -0.2% | -20.8% | |
| Q4 2022 | +8.7% | +13.5% | +7.4% | |
| Q3 2022 | -25.3% | -12.3% | -4.1% | |
| Q2 2022 | -8.3% | -8.8% | -18.5% | |
| Q1 2022 | -5.4% | +6.6% | +8.9% | |
| Q4 2019 | +4.0% | -4.1% | -12.9% | |
| Q4 2021 | +23.4% | +43.1% | +27.6% | |
| Q3 2021 | -11.9% | -8.0% | -13.9% | |
| Q2 2020 | +8.2% | +7.4% | +26.8% | |
| Q2 2021 | +10.6% | +23.9% | +30.3% | |
| Q1 2021 | +12.8% | +15.9% | +44.7% | |
| Q4 2020 | +2.8% | -0.9% | -10.0% | |
| Q3 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro